Body-identical hormone therapy
Body-identical hormone therapy delivers hormones structurally identical to endogenous ones using regulator-approved pharmaceutical products, typically transdermal 17-beta estradiol and oral micronized progesterone. The British Menopause Society classes it as regulated bioidentical HRT (rBHRT) and recommends it in preference to compounded bioidentical preparations, which do not pass through the same regulatory pathway. In the Atlas it is recorded as a distinct value from compounded bioidentical hormone therapy, because the difference is regulatory rather than chemical. It is used by operators in the United Kingdom, Germany, the Nordics and the Gulf. Evidence tier: well-evidenced.
What it is
Body-identical hormone therapy uses hormones structurally identical to those the human body produces, supplied as regulator-approved pharmaceutical products. In the United Kingdom that means preparations authorized by the MHRA; the British Menopause Society calls this class regulated bioidentical hormone replacement therapy, or rBHRT. In practice it means micronized 17-beta estradiol delivered transdermally and micronized progesterone taken orally, both manufactured to pharmacopoeial standard, batch-tested for purity and potency, and prescribable within the NHS. The distinction from compounded bioidentical hormone therapy is regulatory, not chemical, and the Atlas records the two as separate values that are never treated as synonyms. Both classes use molecules identical to endogenous hormones. Only this one passes through a medicines regulator. The British Menopause Society position is explicit that the benefits sought from bioidentical hormones can be obtained through conventionally licensed products without recourse to compounded preparations. Operators that use the phrase deliberately are signalling alignment with NICE and BMS guidance rather than with the compounding market.
Who it is for
Women who are candidates for menopause hormone therapy and, in the operator's framing or their own, want regulator-approved preparations rather than pharmacy-compounded ones. It suits women who intend to remain within guideline-aligned care, those who may move between private and public provision and need prescriptions that transfer, and those for whom documented dose accuracy matters, notably anyone relying on progesterone for endometrial protection. The clinical population is otherwise identical to that for menopause hormone therapy generally.
What to expect
Assessment and titration follow the standard menopause hormone therapy pathway. What differs is the product: transdermal estradiol as a patch, gel or spray, and oral micronized progesterone, both licensed products dispensed against a normal prescription. Operators using this term typically make the regulatory point explicitly in their patient materials, and several in the Atlas do so in quotation marks, marking it as a term of art rather than plain description. Mediclinic in Dubai and Abu Dhabi writes body-identical HRT in quotes; Newson Clinic in the United Kingdom states plainly that it prescribes body identical hormones, naming progesterone, estradiol and testosterone; Menomedikum in Hamburg lists body-identical hormone therapy in its English-language service list. Review cadence, endometrial protection requirements and monitoring are those of any guideline-aligned hormone therapy.
History and background
The term arose in the United Kingdom and the Nordic markets in the 2010s as a way to reclaim the chemical claim of the bioidentical compounding industry for regulated medicine. Compounding pharmacies had built a market on the argument that hormones identical to the body's own were preferable to conjugated equine estrogens, which was chemically reasonable, while attaching to it an unregulated, individually formulated supply model that was not. The 2019 British Menopause Society consensus statement formalized the split, naming rBHRT and cBHRT as distinct classes and recommending against the compounded form on purity, potency and endometrial safety grounds. The 2020 National Academies review reached a parallel conclusion in the United States. The vocabulary did not travel uniformly: German and Austrian operators say bioidentisch where the United Kingdom and Nordic markets say body-identical or kroppsidentisk, so the same word can sit on either side of the regulatory line depending on the market.
Worth knowing
The clearest way to read this term is as a regulatory claim wearing chemical clothing. Nothing about the molecule distinguishes body-identical from compounded bioidentical estradiol; the difference is entirely in who verified the dose. Language geography matters more here than in any other term in this branch. A German or Austrian clinic writing bioidentische Hormone may be describing regulated products, compounded ones, or both, and the word alone does not resolve it, which is why the Atlas splits the values on regulatory status rather than on the operator's chosen adjective. Several operators write the phrase in quotation marks on their own pages, which is itself a signal: they are citing a category, not describing a product.
Offered across the Atlas 7
Related modalities